Prodrug strategies for improved efficacy of nucleoside antiviral inhibitors

Current Opinion in HIV and AIDS

Volumn 8, Issue 6, 2013, Pages 556-564

  Hurwitz, Selwyn J ^a,b   Schinazi, Raymond F ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

adenovirus; antiviral agents; hepatitis B virus; hepatitis C virus; herpes simplex virus; HIV; nucleoside antiviral agents; prodrugs

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; ACICLOVIR; AMDOXOVIR; AMVIR; ANTIVIRUS AGENT; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; FAMCICLOVIR; MERICITABINE; NUCLEOSIDE ANTIVIRAL INHIBITOR; PENCICLOVIR; PRODRUG; SOFOSBUVIR; TENOFOVIR; TENOFOVIR 3 HEXADECYLOXYPROPYL ESTER; TENOFOVIR ALAFENAMIDE; UNCLASSIFIED DRUG; VALACICLOVIR;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG POTENCY; HEPATITIS C; HUMAN; INTESTINE ABSORPTION; LIPID BILAYER; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HUMANS; NUCLEOSIDES; PRODRUGS; VIRUS DISEASES;

EID: 84886096395     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000007     Document Type: Review

References (65)

1. De Clercq E. Antiviral drug discovery and development: where chemistrymeets with biomedicine. Antiviral Res 2005; 67:56-75.
2. Schinazi RF, Hernandez-Santiago BI, Hurwitz SJ. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Res 2006; 71:322-334.
3. De Clercq E, Bernaerts R, Shealy YF, Montgomery JA. Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine. Biochem Pharmacol 1990; 39:319-325.
4. Chou R, Hartung D, Rahman B, et al. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2013; 158:114-123.
5. Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011; 66:2715-2725.
6. Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res 2010; 85:39-58.
7. Dixit NM, Perelson AS. Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J Theor Biol 2004; 226:95-109.
8. Hurwitz SJ, Asif G, Schinazi RF. Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine. Antivir Chem Chemother 2007; 18:329-341.
9. Dahari H, Shudo E, Ribeiro RM, Perelson AS. Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology 2009; 49:32-38.
10. Rong L, Perelson AS. Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents. Math Biosci 2013; 245:22-30.
11. Hurwitz SJ, Schinazi RF. Practical considerations for developing nucleoside reverse transcriptase inhibitors. Drug Discov Today Technol 2012; 9:e183-e193.
12. Ray AS, Hostetler KY. Application of kinase bypass strategies to nucleoside antivirals. Antiviral Res 2011; 92:277-291.
13. Bronson JJ, Ho HT, De Boeck H, et al. Biochemical pharmacology of acyclic nucleotide analogues. Ann N Y Acad Sci 1990; 616:398-407.
14. Hediger MA, Romero MF, Peng JB, et al. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch 2004; 447:465-468.
15. Lalanne M, Andrieux K, Couvreur P. Strategies to increase the oral bioavailability of nucleoside analogs. Curr Med Chem 2009; 16:1391-1399.
16. Imai T, Ohura K. The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr Drug Metab 2010; 11:793-805.
17. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39:1546-1553.
18. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123:89-96.
19. Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet 1996; 31:1-8.
20. De Clercq E, Field HJ. Antiviral prodrugs: the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006; 147:1-11.
21. McDonald EM, de Kock J, Ram FSF. Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials. Antivir Ther 2012; 17:255-264.
22. Bacon TH. Famciclovir, from the bench to the patient: a comprehensive review of preclinical data. Int J Antimicrob Agents 1996; 7:119-134.
23. Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 1997; 25:805-813.
24. Clarke SE, Harrell AW, Chenery RJ. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab Dispos 1995; 23:251-254.
25. Vere Hodge RA, Darlison SJ, Readshaw SA. Use of isotopically chiral [40 -13C]famciclovir and 13C NMR to identify the chiral monoacetylated intermediates in the conversion of famciclovir to penciclovir by human intestinal wall extract. Chirality 1993; 5:577-582.
26. Cundy KC, Sueoka C, Lynch GR, et al. Pharmacokinetics and bioavailability of the antihuman immunodeficiency virus nucleotide analog 9-[(R)-2- (phosphonomethoxy) propyl]adenine (PMPA) in dogs. Antimicrob Agents Chemother 1998; 42:687-690.
27. Shaw JP, Sueoko CM, Oliyai R, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res 1997; 14:1824-1829.
28. Naesens L, Bischofberger N, Augustijns P, et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2- phosphonylmethoxypropyl) adenine in mice. Antimicrob Agents Chemother 1998; 42:1568-1573.
29. Hurwitz SJ, Asif G, Fromentin E, et al. Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1- infected individuals. Antimicrob Agents Chemother 2010; 54:1248-1255.
30. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009; 82:A84-A98; Epub 2009/05/09..
31. Trost LC, Lanier ER, Lampert B, Painter GR. Preclinical evaluation of CMX157: a lipid-conjugated nucleotide analog for the treatment of HIV. 49th Meeting of the Society of Toxicology (SOT), 2010; Abstract # 1057- 216; Salt Lake City, UT, USA.
32. Painter W, Robertson A, Trost LC, et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broadspectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012; 56:2726-2734.
33. Tippin TK, Lampert BM, Painter GR, Lanier ER. Lipid conjugates of cidofovir and tenofovir are not substrates of human organic ion transporters hOAT1 and hOAT3. World Congress and American Association of Pharmaceutical Scientists, 2010; Abstract #T3396; New Orleans, LA, USA.
34. Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010; 285:34337-34347.
35. Murakami E, Niu CR, Bao HY, et al. The mechanism of action of beta-D-20- deoxy-20-fluoro-20-C-methylcytidme involves a second metabolic pathway leading to beta-D-20-deoxy-2-fluoro-20-C-methyluridine 50-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2008; 52:458-464.
36. Ma H, Jiang WR, Robledo N, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2 0-deoxy-2 0-fluoro-2 0-Cmethylcytidine (PSI-6130) and identification of a novel active 5 0-triphosphate species. J Biol Chem 2007; 282:29812-29820.
37. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24:25-36.
38. Lombardo F, Waters NJ, Argikar UA, et al. Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. J Clin Pharmacol 2013; 53:178-191.
39. Poulin P, Hop CE, Ho Q, et al. Comparative assessment of in vitro-in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs. J Pharm Sci 2012; 101:4308-4326.
40. Thompson CM, Johns DO, Sonawane B, et al. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J Toxicol Environ Health B Crit Rev 2009; 12:1-24.
41. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 2012; 92:50-61.
42. Jones HM, Mayawala K, Poulin P. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J 2013; 15:377-387.
43. Cho A, Zhang L, Xu J, et al. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. J Med Chem 2013; Epub ahead of print. GS-6620 had variable pharmacokinetics and efficacy in humans despite reproducible pharmacokinetics in dogs.
44. Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 2005; 49:1898-1906.
45. Birkus G, Kutty N, He GX, et al. Activation of 9-[(R)-2-[[(S)-[[(S)-1- (Isopropoxycarbonyl) ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonamidate prodrugs by human proteases. Mol Pharmacol 2008; 74:92-100.
46. Jin F, Fordyce M, Garner W, et al. Pharmacokinetics, metabolism and excretion of tenofovir alafenamide (TAF). 14th International Workshop on Clinical Pharmacology of HIV Therapy, 2013; Amsterdam, The Netherlands.
47. Margot M, Liu Y, Babusis D, et al., editors. Antiviral activity of tenofovir alafenamide (TAF) against major NRTI-resistant viruses: improvement over TDF/TFV is driven by higher TFV-DP loading in target cells. International Workshop on HIVHepatitis Virus Drug Resistance and Curative Strategies, 2013; Abstract #23; Toronto, ON, Canada.
48. Hoffmann CJ, Ledwaba J, Li JF, et al. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther 2013; Epub 2013/06/12.
49. Hurwitz SJ, Asif G, Kivel NM, Schinazi RF. Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model. Antimicrob Agents Chemother 2008; 52:4241-4250.
50. Michailidis E, Ryan EM, Hachiya A, et al. Hypersusceptibility mechanism of tenofovir-resistant HIV to EFdA. Retrovirol 2013; 10:65.
51. Ruane P, DeJesus E, Berger D, et al. GS-7340 25 mg and 40 mg demonstrate superior efficacy to tenofovir 300mg in a 10-day monotherapy study of HIV-1patients. 18th Conference on Retroviruses and Opportunistic Infections, 2012; Abstract # 568; Boston, MA, USA.
52. Markowitz M, Zolopa A, Ruane P, et al. GS-7340 demonstrates greater declines in HIV-1 RNA than tenofovir disoproxil fumarate during 14 days of monotherapy in HIV-1 infected subjects. 18th Conference on Retroviruses and Opportunistic Infections, 2011; Abstract # 568; Boston, MA, USA.
53. Zolopa A, Ortiz R, Sax P, et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. 20th Conference on Retroviruses and Opportunistic Infections (CROI), 2013; Abstract # 99LB; Atlanta, GA, USA.
54. Painter GR, Almond MR, Trost LC, et al. Evaluation of hexadecyloxypropyl-9- R-[2-(Phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother 2007; 51:3505-3509.
55. Lanier R, Lampert B, Robertson A, et al. Hexadecyloxypropyl tenofovir associates directly with HIV and subsequently inhibits viral replication in untreated cells. 16th Conference on Retroviruses and Opportunistic Infections, 2009; Abstract # 556, Montreal, Canada.
56. Quenelle DC, Lampert B, Collins DJ, et al. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis 2010; 202:1492-1499.
57. Quenelle DC, Prichard MN, Keith KA, et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother 2007; 51:4118-4124.
58. Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 2012; 18:731-738.
59. Clark JL, Mason JC, Hollecker L, et al. Synthesis and antiviral activity of 2-deoxy-2-fluoro-2-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. Bioorg Med Chem Lett 2006; 16:1712-1715.
60. Pawlotsky JM, Najera I, Jacobson I. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther 2012; 17:411-423.
61. Murakami E, Bao HY, Ramesh M, et al. Mechanism of activation of beta-D-2- deoxy-2-fluoro-2-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 2007; 51:503-509.
62. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-1887.
63. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-1877.
64. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381:2100-2107.
65. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368:34-44.